NEW YORK – Invivoscribe announced Thursday that its test for FLT3 mutations in patients with leukemia has achieved regulatory compliance in the UK and Switzerland.

Invivoscribe, a global leader in precision diagnostics, is pleased to announce the successful listings of the LeukoStrat CDx FLT3 Mutation Assay in both the United Kingdom (UK) and Switzerland. The ...

Actinium Pharmaceuticals, Inc.  (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced ATNM-400, a novel, non-PSMA targeting, first in class radiotherapy ...

Invivoscribe, a global leader in precision diagnostics, is pleased to announce the successful listings of the LeukoStrat CDx FLT3 Mutation Assay in ...

Company reports acceptance of an abstract at the 2025 American Society of Clinical Oncology (ASCO) conference; Continues to ...

StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Free Report) in a report published on Wednesday. The brokerage issued a sell rating on the stock. Ayala Pharmaceuticals ...

The development of advanced radiotherapy technologies has, in turn, resulted in an increased complexity of operations. Also, a high level of accuracy is needed at every step of the process to achieve ...

The development of advanced radiotherapy technologies has, in turn, resulted in an increased complexity of operations. Also, a high level of accuracy is needed at every step of the process to achieve ...

TURKU, FI / ACCESS Newswire / March 27, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) New analysis and biomarker data strengthens understanding of bexmarilimab's potentialTURKU, FINLAND - Faron P ...

The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing ...